Daily treatment with the investigational oral therapy lanifibranor — used alone or in combination with the diabetes medication Jardiance…
Lindsey Shapiro, PhD
Lindsey earned her PhD in neuroscience from Emory University in Atlanta, where she studied novel therapeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimer’s disease.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Lindsey Shapiro, PhD
ALAGILLE SYNDROME
NewsIBAT inhibitors have potential to boost life quality for patients
Alagille syndrome comes with a high clinical, economic, and quality-of-life burden for patients and their families, but new…
CHOLANGITIS
NewsLiver donor type may sway primary sclerosing cholangitis outcomes
Liver transplants from a living donor may mean a lower success and a higher need for a second transplant relative…
ALAGILLE SYNDROME
NewsNew app designed to be health record, journal for patients
Know Rare, a support platform for people living with rare diseases such as Alagille syndrome, launched a health…
A two-month course of an oral antiviral treatment combination of bemnifosbuvir and ruzasvir was well tolerated and led to…
FATTY LIVER DISEASE
NewsPoor sleep patterns evident in people with MASLD, MASH: Study
Troubled sleep is more common in people with metabolic dysfunction-associated steatotic liver disease (MASLD), a type of fatty liver…
A peer-supported telemedicine program in the U.S. significantly increased the likelihood that hepatitis C patients in rural communities would…
CHOLANGITIS
NewsPBC therapy Ocaliva pulled from EU market with court decision
Ocaliva (obeticholic acid) is no longer available to treat primary biliary cholangitis (PBC) across the European Union…
Treatment with linerixibat, an oral medication in development by GlaxoSmithKline (GSK), led to significant reductions in pruritus, or itching,…
FATTY LIVER DISEASE
NewsSemaglutide shows liver benefits in Phase 3 MASH trial
Weekly injections of semaglutide, a medication sold in the U.S. under brand names including Ozempic and Wegovy to treat type…